AOD 9604 research did not deliver the hoped-for weight loss
AOD-9604 had an appealing idea behind it. The human result is the part I wouldn't skip: the obesity programme didn't prove the extra weight loss researchers were looking for.
The idea and the result
AOD-9604 is a small, altered piece of growth hormone. Researchers wanted some of the hormone's effects on fat metabolism without its growth-related effects. I can see the appeal, but a clever design still has to work in people.
The human safety and tolerability review describes tolerability broadly similar to placebo, the comparison treatment without the active drug. The larger obesity programme didn't establish a meaningful extra weight-loss benefit and was stopped. Tolerability and benefit are two different questions.
Earlier mouse research helps explain the interest. The lasting weight response changed when mice lacked a particular receptor, a structure that receives a chemical signal. That's useful biology to investigate, but it doesn't tell an adult what result to expect.
A different route needs its own evidence
Much of the human programme used AOD-9604 by mouth. That safety account doesn't automatically cover an injection or another preparation. The route is part of what was tested, even if the name stays the same.
This is a useful question to carry into any discussion: does the evidence match the preparation being described? I don't want a familiar ingredient name to do the work of an actual answer.
The safety questions are still there
AOD-9604 has no FDA-approved medical use. On FDA's safety-risk page, current as of April 22, 2026, it appears under nominations that were withdrawn. It is no longer in that page's Category 2 table.
That change isn't clearance for compounding. FDA still lists concerns about immune reactions and peptide-related impurities beside AOD-9604. The agency gives no withdrawal date for the individual substance, so the page date isn't a date when FDA moved it.
Long-term and rare harms are poorly understood. Material labelled for research can add uncertainty about what's actually in it. A report of no soreness or swelling can't answer those wider safety questions.
What the comparison can tell you
Tesamorelin also touches growth-hormone biology, which explains why the names get paired. Its evidence concerns a specific kind of deep abdominal fat in adults with HIV. Shared biology doesn't make the two interchangeable.
The side-by-side questions keep that difference clear. For me, AOD-9604's most useful lesson is simple: an interesting explanation of how something might work isn't the same as a demonstrated benefit.